Clinical Trial Update: PHA-739358 for Treatment of Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of PHA-739358 in metastatic castration-resistant prostate cancer; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• PHA-739358

Snippet

Sponsor: Nerviano Medical Sciences | Conditions: Metastatic Hormone Refractory Prostate Cancer | Phase 2 | Status: COMPLETED